{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:46:49Z","timestamp":1773337609435,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We assessed race, ethnicity, and geographic diversity in pivotal trials of biologic and targeted synthetic disease\u2010modifying antirheumatic drugs approved for psoriatic arthritis (PsA) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a descriptive epidemiologic study, examining the reporting and representation of race, ethnicity, and geographic distribution of trial sites in pivotal PsA trials using data from journal publications, the Drugs@FDA database, and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 29 pivotal PsA trials for 16 targeted therapies with start dates between 2000 and 2019. Race data were reported in 93% of trials. Race reporting was highest in journal publications (86%); however, among these, 46% reported only the proportion of White participants. Ethnicity data were available for 41% of trials, primarily from\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      , with improved reporting in recent years. Among 14,165 participants in 27 trials with race data, 92% were White, 7% were Asian, and fewer than 1% were Black, American Indian\/Alaska Native, or Native Hawaiian\/Pacific Islander. Among 8,105 participants in 12 trials with ethnicity data, 11% were Hispanic or Latino individuals. Location data were available for 26 trials. In the United States, trial activity was highest in Texas (24 trials), Florida and Pennsylvania (22 each), and California (20), strongly correlating with state population size (r = 0.78,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). Globally, trial sites were identified in 55 countries, primarily in North America and Europe, with fewer sites in Asia, Africa, and Latin America.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Racial and ethnic diversity in pivotal PsA trials remains limited. Tailored and multifaceted strategies are needed to improve participant representativeness in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.25574","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:25:27Z","timestamp":1747635927000},"page":"1293-1302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8748-6034","authenticated-orcid":false,"given":"Mathieu","family":"Choufani","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9404","authenticated-orcid":false,"given":"Joerg","family":"Ermann","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-5157","authenticated-orcid":false,"given":"Niti","family":"Goel","sequence":"additional","affiliation":[{"name":"Caduceus Biomedical Consulting, LLC, and Duke University School of Medicine  Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1604635"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMms1604593"},{"key":"e_1_2_7_4_1","unstructured":"US Food and Drug Administration.Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies. Accessed January 29 2025.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/diversity\u2010action\u2010plans\u2010improve\u2010enrollment\u2010participants\u2010underrepresented\u2010populations\u2010clinical\u2010studies"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2215609"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae198"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00370-4"},{"issue":"6","key":"e_1_2_7_8_1","first-page":"48","article-title":"Promoting diversity, equity, and inclusion for psoriatic diseases","volume":"49","author":"Takeshita J","year":"2022","journal-title":"J Rheumatol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.212"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae066"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00717-7"},{"key":"e_1_2_7_12_1","unstructured":"US Food and Drug Administration.Enhancing the diversity of clinical trial populations\u2014eligibility criteria enrollment practices and trial designs; guidance for industry; availability. Accessed January 29 2025.https:\/\/www.federalregister.gov\/documents\/2020\/11\/10\/2020\u201024881\/enhancing\u2010the\u2010diversity\u2010of\u2010clinical\u2010trial\u2010populations\u2010eligibility\u2010criteria\u2010enrollment\u2010practices\u2010and"},{"key":"e_1_2_7_13_1","unstructured":"Food and Drug Omnibus Reform Act (FDORA) of 2022. Accessed August 2 2024.https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/food-and-drug-omnibus-reform-act-fdora-2022"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2024.101331"},{"key":"e_1_2_7_15_1","unstructured":"Office of Management and Budget.Revisions to OMB's Statistical Policy Directive No. 15: standards for maintaining collecting and presenting federal data on race and ethnicity. Accessed August 2 2024.https:\/\/www.federalregister.gov\/documents\/2024\/03\/29\/2024\u201006469\/revisions\u2010to\u2010ombs\u2010statistical\u2010policy\u2010directive\u2010no\u201015\u2010standards\u2010for\u2010maintaining\u2010collecting\u2010and"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106237"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5596"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13304"},{"key":"e_1_2_7_19_1","unstructured":"International Committee of Medical Journal Editors.Recommendations for the conduct reporting editing and publication of scholarly work in medical journals. Accessed November 25 2024.https:\/\/www.icmje.org\/icmje-recommendations.pdf"},{"key":"e_1_2_7_20_1","article-title":"SOPP 8401.7: action package for posting","author":"Center for Biologics Evaluation and Research","year":"2022","journal-title":"US Food and Drug Administration."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.0142"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gloepi.2023.100134"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-1013"},{"key":"e_1_2_7_24_1","unstructured":"Food and Drug Administration Amendments Act of 2007 HR 3580 110th Congress (2007). Pub L No. 110\u201385. Accessed July 20 2024.https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf#page=82"},{"key":"e_1_2_7_25_1","unstructured":"US Food and Drug Administration.Collection of race and ethnicity in clinical trials. Accessed August 2 2024.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/collection\u2010race\u2010and\u2010ethnicity\u2010data\u2010clinical\u2010trials"},{"key":"e_1_2_7_26_1","unstructured":"42 CFR part 11\u2014clinical trials registration and results information submission. Accessed August 2 2024.https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-11"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.08.038"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152175"},{"issue":"9","key":"e_1_2_7_29_1","article-title":"Racial and gender disparities in psoriatic arthritis clinical trials [abstract]","volume":"76","author":"Kaur D","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0728-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14745"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.09.011"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25059"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00754"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2024.101255"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100402"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2024.100500"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2441"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-0653-x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.317"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2025-1"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301706"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481602300404"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081245"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01545-z"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.5103"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/JHL.S488426"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adq4994"},{"issue":"8","key":"e_1_2_7_49_1","first-page":"168","article-title":"The challenges of collecting data on race and ethnicity in a diverse, multiethnic state","volume":"70","author":"Kaneshiro B","year":"2011","journal-title":"Hawaii Med J"},{"key":"e_1_2_7_50_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.General considerations for clinical studies E8(R1).https:\/\/database.ich.org\/sites\/default\/files\/E8-R1_Guideline_Step4_2021_1006.pdf"},{"key":"e_1_2_7_51_1","unstructured":"US Food and Drug Administration.E8(R1) general considerations for clinical studies. Accessed April 10 2025.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/e8r1\u2010general\u2010considerations\u2010clinical\u2010studies"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:55:30Z","timestamp":1761296130000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/acr.25574"],"URL":"https:\/\/doi.org\/10.1002\/acr.25574","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}